This review deals briefly with recent developments in the therapeutic drug monitoring of
digoxin. Strategies for decreasing the interference by digoxin metabolites, digoxin-like …

Theoretischer Hintergrund: Gesundheitsbezogene Lebensqualität (gLQ) stellt einen
wichtigen Aspekt in der Evaluation medizinischer Behandlungen dar. Fragestellung: Der …

Health-related quality of life (HRQL), representing a patient-driven end point, has been
increasingly emphasized in randomized clinical trials of new heart failure therapies …

Background/objectives Digoxin is widely used as symptomatic treatment in heart failure
(HF), but the role in contemporary treatment of HF with sinus rhythm (SR) is debatable. We …

Age-associated physiologic changes predispose older adults to develop heart failure, even
when left ventricular ejection fraction is normal or near normal. Heart failure with a preserved …

Digoxin is commonly used to treat congestive heart failure. Digoxin augments ventricular
systolic performance, but does not benefit patients whose congestive heart failure is caused …

The use of digitalis in congestive heart failure with normal sinus rhythm is still debated.
While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data …

It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

Background The impact of digoxin on outcomes of patients with advanced heart failure (HF)
remains uncertain and its effect may be different for patients in atrial fibrillation (AF) or sinus …

Digoxin is one of the most frequently prescribed drugs, particularly in the elderly population
where there is an increased prevalence of atrial fibrillation and cardiac failure. The drug has …